Working… Menu
Trial record 1 of 1 for:    Abelacimab
Previous Study | Return to List | Next Study

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation (AZALEA-TIMI 71)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04755283
Recruitment Status : Recruiting
First Posted : February 16, 2021
Last Update Posted : December 2, 2021
The TIMI Study Group
Information provided by (Responsible Party):
Anthos Therapeutics, Inc.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : May 2023